期刊文献+

大剂量地塞米松联合硼替佐米及沙利度胺治疗多发性骨髓瘤合并肾衰竭的临床研究 被引量:8

Therapeutic effects of high-dose dexamethasone combined with thalidomide and bortezomib on renal function in patients newly diagnosed multiple myeloma
原文传递
导出
摘要 目的观察以大剂量地塞米松为基础的常规化疗加用硼替佐米及沙利度胺治疗后对多发性骨髓瘤合并急性肾衰竭患者的影响。方法对23例伴肾衰竭的新发骨髓瘤患者均采用大剂量地塞米松加用硼替佐米和沙利度胺治疗,观察患者在用药前后肾损害的改善情况。结果严重肾衰竭的12例患者中逆转1例,好转6例,总有效率58.3%;肾衰竭的11例患者中逆转4例,好转5例,总有效率81.8%。全部病例总有效率69.5%(16/23)。对原发病骨髓瘤治疗总有效率60.9%(14/23)。中位显效时间为2个月(1。5个月)。3年总体生存率为56.5%,中位生存期34.4个月。结论大剂量地塞米松联合硼替佐米和沙利度胺对新发骨髓瘤患者的肾衰竭逆转率高,对原发病治疗效果较好,不良反应少、安全可靠、见效快,可作为一线治疗用药。 Objective To assess the efficacy of high dose dexamethasone combined with bortezomib and thalidomide in muttiple myeloma (MM) patients with acute renal failure. Methods 23 newly diagnosed MM patients with acute renal failure were treated with high dose dexamethasone combined with bortezomib and thalidomide. Results Reversal of renal failure was documented in 58.3 % (7/12) of those severe renal failure patients and 81.8 % (9/11) of renal failure patients.Renal function was reversed in 69.5 % (16/23) of all patients. The total response rate for MM was 60.9 % (14/23). The median time to response was 2 (1-5) months. Overall survival (OS) at 3 years was 56.5 % and the median survival time was 34.4 months. Conclusion Renal failure was reversible in the majority of newly diagnosed MM patients treated with high- dose dexamethasone containing regimens. The addition of novel agents thalidomide and (or) bortezomib is safe and induces a more rapid renal failure reversal compared with routine chemotherapy.
作者 高大 肖镇
出处 《白血病.淋巴瘤》 CAS 2012年第10期604-606,共3页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 肾功能不全 地塞米松 沙利度胺 硼替佐米 Multiple myeloma Renal insufficiency Dexamethasone Thalidomide Bortezomib
  • 相关文献

参考文献13

  • 1Raah MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet, 2009, 374: 324-339.
  • 2Kyle RA, Gertz MA, Witzig TE, et o2. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78:21-33.
  • 3Heher EC, Goes NB, Spitzer TR, et al. Kidney disease associated with plasma cell dyscrasias. Blood, 2010, 116: 1397-1404.
  • 4Ludwig I-I, Beksac M, Blade J, et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oneologist, 2011, 16: 388-403.
  • 5Morabito F, Gentile M, Ciolli S, et al. Safety and effcacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol, 2010, 84: 223-228.
  • 6Synold TW, Takimoto CH, Doroshow JH, et ak Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res, 2007, 13: 3660- 3666.
  • 7Moumas E, Hanf W, Desport E, et al. New insights in the treatment of myeloma with renal failure. Nephrol Ther, 2011, 7: 457-466.
  • 8Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oneol, 2001, 28: 613-619.
  • 9Eda H, Aoki K, Kato S, et al. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like ceils. Eur J Haematol, 2010,85: 68-75.
  • 10Hideshima T, Ikeda I-I, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009. 114: 1046-1052.

同被引文献58

  • 1Blade J, de Larrea CF, Rosifiol L. Extramedullary involvement in multiple myeloma. Haematologica, 2012, 97: 1618-1619.
  • 2International Myel oma Working Group. Criteria for the classification of monocl onal garnmopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 2003, 21: 749-757.
  • 3Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated byhigh-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998, 102:1115-1123.
  • 4Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Ontology, 2010: 325- 330.
  • 5Cerny J, Fadare O, Hutchinson L, et al. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol, 2005, 81: 65-69.
  • 6Franchini M, Frattini F, Crestani S, et al. Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J Thromb Thrombolysis, 2012.
  • 7Aritaka N, Ichikawa K, Nakamura H, et al. Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy. Intern Med, 2012, 51: 2781-2783.
  • 8Decaux 0, Renault A, S~bille V, et al. Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective muhicenter nonrandomized phase 1I study in 120 patients. Clin Lymphoma Myeloma Leuk. 2012, 12:418-422.
  • 9Yasuda H, Ando J, Sato E, et al. Successful treatment of extramedullary tumo with low-dose thalidomide in patients with multiple myeloma. Intern Med, 2010, 49: 2617-2620.
  • 10Blade J, Fernandez C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanism of extarmedullary spread, and treatment approach. J Clin Oncol, 2011, 29: 3805-3812.

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部